Empowering a faster time-to-market for your novel medicine
Our solutions make a difference
The integration of our unique technologies in our equipment, combined with our unique know-how, allow us to guide you with mastering every aspect of the manufacturing process, from laboratory scale to commercial production scale. Whether it is the development of new products or the improvement of existing products, Secoya’s technologies provide many key benefits
- Unmatched product quality and secure production
- Implementation of Quality-by-Design
- Reduction of investment cost and risk for the process development
- Reduction of cost of goods sold
- Inherent compatibility with continuous manufacturing
- Manufacturing of new possible molecules
Our three key principles
The methodology followed by Secoya Technologies to develop new process solutions combines three key principles
Intensification
To us, intensification goes beyond increasing yield and reducing the environmental footprint of processes. It also implies having full control over daily desired production rates and being able to adapt them easily, which has a major impact on the cost of goods.
Thanks to our smart scale-up principle for all our devices, individual output control per single, highly intensified reactor remains possible, to match even the smallest fluctuations in demand. This results in the best possible application of the principles of green chemistry, which is inherent to all our designs.
Integration
All our devices are fully integrated into a specific and complete process design that englobes all necessary instrumentation for in-line follow-up and control, steered pumping systems, cooling and heating elements and other features.
State-of-the-art software guarantees true and full continuous operation with live measurement of all necessary parameters and direct control of all required conditions so that the process will be maintained inside the desired operational frame to obtain steady-state output of the best possible quality.
Quality-by-design
We design robust and tailored processes based on cutting-edge technologies that enable high and consistent quality: the real-time monitoring and steering of all necessary process parameters maintains the process in its predefined operational window.
This drastically reduces the batch-to-batch variability, while at the same time refining product dispersibility, whether it is particle size distribution, attained yield, purity of the end product, etc. As we design the end solution together with our clients, this operational zone is calibrated as a function of actual process variables, which is one of the major benefits of using microfluidic principles in the smart scale-up of our various reactors.
We are proud to collaborate with:
GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.
They prioritise innovation in vaccines and specialty medicines to prevent and treat disease.
Siegfried is a leading contract development and manufacturing organization with more than 3,600 dedicated professionals across 12 production sites on three continents. With their longstanding pharmaceutical and chemical experience, they are taking innovations to an industrial scale.
Minakem is a fully integrated development partner and commercial manufacturer for pharmaceutical companies. All development and manufacturing activities are supported by highly skilled R&D technical centres, strong and state-of-the-art analytical services including solid form and QbD laboratories.
A global leader in sustainable technologies. For over two centuries they’ve used advanced metals chemistry to tackle the world’s most pressing challenges. Today, their renowned customers across the energy, chemicals and automotive industries rely on our technology and knowledge to decarbonise, remove harmful emissions and improve their sustainability.
Fluigent builds on 18 years of pressure-based flow control expertise to bring the most advanced fluid control systems available to the
Research and OEM markets offering greater control, automation and precision.
The objective of the research carried out at the Transfers, Interfaces and Processes (TIPs) laboratory of the Université libre de Bruxelles (ULB) is the experimental characterization and the mathematical modeling of transport phenomena within systems containing several phases (gas and/or liquid and/or solid), exchanging matter, heat or momentum, through an interface between these phases, at scales between the micron and the millimeter.
DFE Pharma is a global leader in pharma- and nutraceutical excipient solutions. We develop, produce and supply high-quality functional excipients for use in the pharmaceutical, biopharmaceutical, and nutraceutical industries for oral solid dose (OSD), respiratory, ophthalmic and parenteral formulations.
The National University of Science & Technology (NU), a private university in the Sultanate of Oman, was established in 2018. It is renowned for its excellence in providing undergraduate and post graduate programs in medicine, pharmacy, engineering, maritime science, and advanced technology.
Janssen is a Pharmaceutical company owned by Jonhson & Jonhson founded in 1953. In over 150 countries, they bring together the most creative minds and cutting-edge technology to help treat, cure, stop, and prevent some of the most complex diseases of our time.
